AMBEV S.A. current report, Q4 FY2022

Business Context and Reporting Period

This Form 6-K filing by AMBEV S.A. reports on a Board of Directors meeting held on December 6, 2022. The document serves as an extract of the minutes detailing corporate governance actions, specifically regarding financial distributions and balance sheet preparations for the period ending October 31, 2022.

Key Financial Metrics

The filing does not provide comprehensive financial statements (revenue, profit, cash flow, or debt levels). The only specific financial metric disclosed is the distribution of Interest on Own Capital (IOC):

  • Gross IOC Distribution: R$0.7623 per share.
  • Net IOC Distribution: R$0.6480 per share (after applicable taxes).
  • Funding Source: Available balances from the extraordinary balance sheet as of October 31, 2022, and the investment reserve from the December 31, 2021 balance sheet.

Material Changes and Corporate Actions

The Board unanimously resolved on the following material actions:

  • Extraordinary Balance Sheet: Approved the preparation of an extraordinary balance sheet as of October 31, 2022.
  • Dividend Attribution: The IOC distribution is attributed to the minimum mandatory dividends for the fiscal year.
  • Payment Schedule:
    • Payment Date: December 29, 2022.
    • Record Dates: December 19, 2022 (B3 S.A.) and December 21, 2022 (NYSE).
    • Ex-IOC Date: December 20, 2022.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, future guidance, outlook, or specific risk factors. The document is strictly a record of the Board's resolutions regarding the IOC distribution and balance sheet preparation.

Investor Verification Checklist

  • Verify the ex-IOC trading date of December 20, 2022, to confirm eligibility for the R$0.6480 net distribution.
  • Confirm the payment date of December 29, 2022, for cash receipt.
  • Review the extraordinary balance sheet dated October 31, 2022, for details on the available balances funding this distribution.
  • Check tax implications for corporate shareholders, as some may be immune or exempt under Article 5 of Law 11,053/04.